CON vs SUPN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Concentra Group Holdings presents a dichotomy between strong growth and precarious leverage. While the Piotroski F-Score of 4/9 indicates stable financial health, the extreme Debt/Equity ratio of 5.01 is a significant risk factor that likely inflates the impressive 48.07% ROE. The stock trades at a significant premium to its Graham Number ($9.46) but remains well below its growth-based intrinsic value ($38.35), suggesting a valuation gap that analysts believe will close, despite a currently bearish technical trend.
SUPN presents a contradictory profile, characterized by a weak Piotroski F-Score of 2/9 and bearish insider sentiment (30/100). Despite these fundamental warnings, the company shows strong top-line growth (21.5% YoY) and maintains a very low debt-to-equity ratio of 0.04. Analysts remain highly optimistic with a 'Strong Buy' consensus and a target price of $63.17, suggesting a disconnect between current operational health and future growth expectations. The stock is currently a speculative play where strong revenue growth is fighting against deteriorating fundamental health metrics.
Compare Another Pair
Related Comparisons
CON vs SUPN: Head-to-Head Comparison
This page compares Concentra Group Holdings Parent, Inc. (CON) and Supernus Pharmaceuticals, Inc. (SUPN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.